How MakeMyTrip’s (MMYT) GenAI Travel Assistant Could Expand Its Market Reach and User Engagement

• Earlier this month, MakeMyTrip introduced a GenAI-enabled Trip Planning Assistant, a comprehensive upgrade to its Myra AI agent, offering voice and text support in both English and Hindi to guide users throughout their travel journey from planning to post-sales support.
• This innovation aims to make online travel booking accessible to a wider audience across India, especially those more comfortable with regional languages, by enabling complex, personalized travel planning in a conversational format.
• We’ll now examine how Myra’s multilingual, end-to-end booking features could reshape MakeMyTrip’s investment narrative by broadening market reach and user engagement.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

MakeMyTrip Investment Narrative Recap

For shareholders, the MakeMyTrip investment story centers on betting that expanding digital travel adoption, especially through product innovation like AI-powered booking tools, will unlock long-term growth in India’s massive but underpenetrated travel market. The recent GenAI-enabled Trip Planning Assistant could accelerate user acquisition and engagement, potentially driving higher booking volumes, a top short-term catalyst, yet, it does little to address the persistent risk that heavy promotional spending may continue weighing on margins if customer acquisition remains structurally costly.

A recently announced buyback plan authorizing repurchases of up to US$3 billion in Class B Shares stands out as relevant to shareholder value creation. While product enhancements like Myra may fuel growth, capital allocation decisions, such as this sizeable buyback, could also impact near-term sentiment, giving investors additional data points to weigh against margin pressures and ongoing competition.

Yet, against optimism for product-driven growth, investors should also keep an eye on whether marketing and promotion spending can realistically...

Read the full narrative on MakeMyTrip (it's free!)

MakeMyTrip's narrative projects $1.8 billion revenue and $289.3 million earnings by 2028. This requires 22.2% yearly revenue growth and an increase in earnings of $189.3 million from $100.0 million.

Uncover how MakeMyTrip's forecasts yield a $120.11 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community range dramatically from US$36.60 to US$180,922.76. While consensus expects expanding digital adoption to be a growth driver, not all investors agree on MakeMyTrip’s true potential, giving you plenty of viewpoints to consider.

Explore 3 other fair value estimates on MakeMyTrip - why the stock might be a potential multi-bagger!

Build Your Own MakeMyTrip Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your MakeMyTrip research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free MakeMyTrip research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MakeMyTrip's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com